Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges

Инновационные стратегии формулирования для биосимиляров: тенденции, фокусированные на системах без буфера, безопасности, регуляторной согласованности и проблемах интеллектуальной собственности
Tomás Gabriel Bas
2025-06-17

AI-based in silico simulationsProcess-Analytical-Technology (PAT)Quality-by-Design (QbD)buffer-free high-concentration systemsintellectual property challengespatent thicketsprotein self-bufferingregulatory flexibility (FDA and EMA)
The formulation of biosimilar products critically determines their stability, safety, immunogenicity, and market accessibility. This article presents a novel integrative framework for biosimilar formulation that balances scientific, regulatory, and intellectual property dimensions, offering a holistic perspective rarely unified in the literature. It highlights the growing trend toward buffer-free, high-concentration systems that leverage protein self-buffering to improve patient comfort and formulation stability. The article also addresses regulatory flexibility from the FDA and EMA, which allows scientifically justified deviations from reference formulations to ensure pharmaceutical equivalence and minimize immunogenicity. A novelty of this article is its comprehensive analysis of how digital innovations, such as Quality-by-Design, Process-Analytical-Technology, and AI-based in silico simulations, are transforming formulation design and bioprocess optimization to reduce immunogenic risks and enhance bioequivalence. Two important key takeaways emerge: (1) strategic innovation in formulation, especially using buffer-free and high concentration systems, improve product stability and patient tolerability while complying with regulatory standards; and (2) intellectual property challenges, including patent thickets, strongly influence formulation decisions, making early legal-strategic alignment essential for market entry. The article confirms that practical recommendations for the selection of recombinant therapeutic protein formulations can effectively guide developers and regulators toward safer, more efficient, and commercially viable biosimilar products.
1
Biosimilar formulation critically affects stability, safety, immunogenicity, and market accessibility.
2
Digital innovations (Quality-by-Design, Process-Analytical-Technology, AI-based in silico simulations) transform formulation design and bioprocess optimization to reduce immunogenic risks and enhance bioequivalence.
3
Intellectual property challenges, including patent thickets, strongly influence formulation decisions, necessitating early legal-strategic alignment for market entry.
4
Practical recommendations for selecting recombinant therapeutic protein formulations can guide developers and regulators toward safer, more efficient, and commercially viable biosimilars.
5
Regulatory agencies (FDA and EMA) show flexibility allowing scientifically justified deviations from reference formulations to ensure pharmaceutical equivalence and minimize immunogenicity.
6
Strategic innovation in formulation combined with regulatory compliance enables improved product stability and patient tolerability.
7
Trend toward buffer-free, high-concentration systems leveraging protein self-buffering improves patient comfort and formulation stability.

Formulation strategies for biosimilar recombinant therapeutic protein products

Impact of buffer-free, high-concentration systems and integrative design (including safety, stability, immunogenicity, regulatory alignment, digital QbD/PAT/AI tools, and intellectual property constraints) on product stability, patient tolerability, bioequivalence, and market access

Publication Details
Publication Date
2025-06-17
Journal
Publisher
ISSN
Cited by
33
Access Type
Author Information
Authors
Tomás Gabriel Bas
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%